BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 08, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Vidaza azacitidine: Phase III started

Celgene disclosed in its 3Q10 earnings that it began an open-label, international Phase III trial to evaluate once-daily 75 mg/m 2 subcutaneous Vidaza for the first 7 days of a 28-day cycle vs. standard of care (SOC) in 480 elderly...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >